Rui-Zhi Tan, Hui Diao, Jian-Chun Li, Xia Zhong, Xiao-Jia Wang, Dan Wen, Jun-Ming Fan, Li Wang
Research Center for Integrated Chinese and Western Medicine, Affiliated Traditional Medicine Hospital, Southwest Medical University, Luzhou, China.
Department of Nephrology, Affiliated Hospital of Southwest Medical University, Luzhou, China.
Front Physiol. 2020 Nov 27;11:583668. doi: 10.3389/fphys.2020.583668. eCollection 2020.
There is increasing evidence that Chronic Kidney Disease (CKD) can cause intestinal dysfunction, which in turn aggravates the progression of kidney disease. Studies have shown that the immune response of macrophage plays an important role in promoting inflammation in kidney and intestine of CKD. Bunge and Panax notoginseng formula (A&P) is a widely used traditional medicine for the treatment of CKD in China, however, the underlying mechanism is largely unclear. In this study, we aimed to explore the role of A&P and Bifidobacterium combination treatment in regulation of inflammatory response of macrophage in kidney and intestine of CKD mouse, as well as the potential molecular mechanism. We established a CKD mouse model with 5/6 nephrectomy and a macrophage inflammatory cellular model with LPS and urotoxin and . The results showed that A&P combined with Bifidobacterium significantly reduced the expression and secretion of IL-1β, IL-6, TNFα, and MCP-1 in kidney and blood, as well as in inflammatory macrophage. Interestingly, A&P combined with Bifidobacterium strongly improved the intestinal flora and protected the intestinal barrier. Notably, the maintainer of macrophage polarization, Mincle, was activated in kidney and intestine of CKD mouse as well as in urotoxin stimulated macrophage, that was effectively inhibited by the treatment of A&P and Bifidobacterium combination. Overexpression of Mincle by genetic modification can abolish the inhibitory effects of A&P combined with Bifidobacterium on inflammation in urotoxin stimulated RAW264.7 cells. In summary, these findings demonstrated that A&P combined with Bifidobacterium can protect kidney against CKD by down-regulating macrophage inflammatory response in kidney and intestine via suppressing Mincle signaling, which provides a new insight in the treatment of CKD with traditional medicine.
越来越多的证据表明,慢性肾脏病(CKD)可导致肠道功能障碍,进而加重肾脏疾病的进展。研究表明,巨噬细胞的免疫反应在促进CKD患者肾脏和肠道炎症中起重要作用。 大黄和三七配方(A&P)是中国广泛用于治疗CKD的传统药物,然而,其潜在机制在很大程度上尚不清楚。在本研究中,我们旨在探讨A&P与双歧杆菌联合治疗对CKD小鼠肾脏和肠道巨噬细胞炎症反应的调节作用及其潜在分子机制。我们通过5/6肾切除建立了CKD小鼠模型,并通过脂多糖(LPS)和尿毒素建立了巨噬细胞炎性细胞模型。结果表明,A&P联合双歧杆菌显著降低了肾脏、血液以及炎性巨噬细胞中白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNFα)和单核细胞趋化蛋白-1(MCP-1)的表达和分泌。有趣的是,A&P联合双歧杆菌能显著改善肠道菌群并保护肠道屏障。值得注意的是,巨噬细胞极化的维持因子小C型凝集素(Mincle)在CKD小鼠的肾脏和肠道以及尿毒素刺激的巨噬细胞中被激活,而A&P与双歧杆菌联合治疗可有效抑制这种激活。通过基因改造过表达Mincle可消除A&P联合双歧杆菌对尿毒素刺激的RAW264.7细胞炎症的抑制作用。总之,这些发现表明,A&P联合双歧杆菌可通过抑制Mincle信号通路下调肾脏和肠道巨噬细胞的炎症反应,从而保护肾脏免受CKD侵害,这为传统药物治疗CKD提供了新的见解。